ESR1 and breast cancer: In summary, RGC-32 is involved in cell proliferation and tamoxifen resistance in ER+ breast cancer, which can potentially be employed as a prognostic biomarker for the progression of ER+ breast cancer, as well as a predictive biomarker for tamoxifen resistance.